Wall Street brokerages expect MediWound Ltd. (NASDAQ:MDWD) to report earnings of ($0.20) per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for MediWound’s earnings. The highest EPS estimate is ($0.19) and the lowest is ($0.22). MediWound reported earnings of ($0.26) per share in the same quarter last year, which suggests a positive year over year growth rate of 23.1%. The firm is expected to report its next quarterly earnings results on Monday, November 13th.

On average, analysts expect that MediWound will report full-year earnings of ($0.81) per share for the current financial year, with EPS estimates ranging from ($0.87) to ($0.76). For the next financial year, analysts anticipate that the firm will report earnings of ($0.75) per share, with EPS estimates ranging from ($1.10) to ($0.48). Zacks’ EPS calculations are an average based on a survey of research analysts that cover MediWound.

MediWound (NASDAQ:MDWD) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.01. The company had revenue of $0.69 million during the quarter, compared to analyst estimates of $0.69 million. MediWound had a negative net margin of 752.78% and a negative return on equity of 326.32%. The company’s revenue for the quarter was up 93.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.34) EPS.

MDWD has been the topic of several recent research reports. SunTrust Banks, Inc. reissued a “buy” rating on shares of MediWound in a report on Monday, June 26th. Aegis reissued a “buy” rating and issued a $11.00 price target on shares of MediWound in a report on Thursday, May 25th. Oppenheimer Holdings, Inc. set a $10.00 price target on MediWound and gave the stock a “buy” rating in a report on Monday, May 8th. Finally, Zacks Investment Research raised MediWound from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 2nd. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $10.19.

A number of hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN increased its stake in shares of MediWound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 8,745 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of MediWound by 11.9% in the fourth quarter. Renaissance Technologies LLC now owns 74,300 shares of the biopharmaceutical company’s stock valued at $340,000 after buying an additional 7,900 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in shares of MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock valued at $14,241,000 after buying an additional 213,745 shares during the last quarter. 27.32% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Brokerages Expect MediWound Ltd. (MDWD) to Post -$0.20 EPS” was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/brokerages-expect-mediwound-ltd-mdwd-to-post-0-20-eps/1466435.html.

MediWound (MDWD) traded down 3.60% on Wednesday, hitting $6.70. The stock had a trading volume of 27,464 shares. MediWound has a 12-month low of $4.25 and a 12-month high of $8.58. The company’s 50 day moving average price is $6.96 and its 200-day moving average price is $6.41. The company’s market cap is $146.93 million.

MediWound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Get a free copy of the Zacks research report on MediWound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.